[go: up one dir, main page]

PE20081252A1 - Derivados de espiro-piperidina - Google Patents

Derivados de espiro-piperidina

Info

Publication number
PE20081252A1
PE20081252A1 PE2007001736A PE2007001736A PE20081252A1 PE 20081252 A1 PE20081252 A1 PE 20081252A1 PE 2007001736 A PE2007001736 A PE 2007001736A PE 2007001736 A PE2007001736 A PE 2007001736A PE 20081252 A1 PE20081252 A1 PE 20081252A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
alcoxy
spyro
indol
Prior art date
Application number
PE2007001736A
Other languages
English (en)
Inventor
Caterina Bissantz
Christophe Grundschober
Raffaello Masciadri
Hasane Ratni
Mark Rogers-Evans
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081252A1 publication Critical patent/PE20081252A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO-PIPERIDINA DE FORMULA (I) DONDE X ES C=O, CH2, O, NR7, EN DONDE R7 ES H O ALQUILO(C1-C6); Y ES O, CH2, C=O; O X-Y ES -C=C- O -CH2-CH2-; R1 ES H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON CN U OH, O -(ALQUILENO(C1-C6))-C(O)-NRaRb, DONDE Ra Y Rb SON CADA UNO H, ALQUILO(C1-C6), ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS; R3 ES H, HALOGENO O ALQUILO(C1-C6); R4 ES H, HALOGENO, ALQUILO(C1-C6), ALCOXI(C1-6), ENTRE OTROS; R5 ES H, HALOGENO, ALCOXI(C1-C6), ENTRE OTROS; R6 ES H, NITRO, CN, HALOGENO, ENTRE OTROS; R8, R9, R10 Y R11 SON CADA UNO H, HALOGENO, ALQUILO(C1-C6), ALCOXI(C1-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {5-CLORO-2-[(3-OXO-1'H,3H-ESPIRO[2-BENZOFURANO-1,4'-PIPERIDIN]-1'-IL)CARBONIL]-1H-INDOL-7-IL}ACETONITRILO, 2-{5-CLORO-2-[(3-OXO-1'H,3H-ESPIRO[2-BENZOFURANO-1,4'-PIPERIDIN]-1'-IL)CARBONIL]-1H-INDOL-1-IL}-N,N-DIMETILACETAMIDA, 1'-[(5-CLORO-1H-INDOL-2-IL)CARBONIL]-3H-ESPIRO[2-BENZOFURANO-1,4'-PIPERIDIN]-3-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA VASOPRESINA V1a SIENDO UTILES EN EL TRATAMIENTO DE ANSIEDAD, DEPRESION, DISMENORREA, FALLO CARDIACO CRONICO
PE2007001736A 2006-12-07 2007-12-06 Derivados de espiro-piperidina PE20081252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125634 2006-12-07

Publications (1)

Publication Number Publication Date
PE20081252A1 true PE20081252A1 (es) 2008-09-04

Family

ID=39295880

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001736A PE20081252A1 (es) 2006-12-07 2007-12-06 Derivados de espiro-piperidina

Country Status (21)

Country Link
US (3) US20080139554A1 (es)
EP (1) EP2102207B1 (es)
JP (1) JP2010511661A (es)
KR (1) KR101050568B1 (es)
CN (1) CN101547923A (es)
AR (1) AR064135A1 (es)
AT (1) ATE469900T1 (es)
AU (1) AU2007328995B2 (es)
BR (1) BRPI0720004A2 (es)
CA (1) CA2670674A1 (es)
CL (1) CL2007003482A1 (es)
DE (1) DE602007006990D1 (es)
ES (1) ES2344131T3 (es)
IL (1) IL198544A (es)
MX (1) MX2009005504A (es)
NO (1) NO20091830L (es)
PE (1) PE20081252A1 (es)
RU (1) RU2009119394A (es)
TW (1) TW200838518A (es)
WO (1) WO2008068185A1 (es)
ZA (1) ZA200903496B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
EP2722333A1 (en) 2008-04-29 2014-04-23 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases.
KR20170084047A (ko) * 2014-11-14 2017-07-19 에프. 호프만-라 로슈 아게 스피로-티아졸론
CN108884096B (zh) * 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
EP3679043B9 (en) * 2017-09-05 2023-09-27 Neumora Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) * 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) * 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) * 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) * 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
CA2037287A1 (en) * 1990-03-02 1991-09-03 Ben E. Evans Spirocyclic oxytocin antagonists
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
AU5292393A (en) 1992-10-07 1994-04-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
CA2240108A1 (en) 1995-12-14 1997-06-19 Peter Lin Antagonists of gonadotropin releasing hormone
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
IL152177A0 (en) 2000-05-12 2003-05-29 Solvay Pharm Bv Piperazine and piperidine compounds
TR200401316T4 (tr) 2000-09-29 2004-07-21 Eli Lilly And Company Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
ES2303558T3 (es) 2001-11-27 2008-08-16 F. Hoffmann-La Roche Ag Derivados de benzotiazol.
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
WO2004026855A1 (en) 2002-09-20 2004-04-01 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
WO2004035549A1 (en) 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
WO2004069809A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
EP2239012A3 (en) * 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
WO2005046682A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
GEP20084571B (en) * 2003-12-22 2008-12-25 Pfizer Triazole derivatives as vasopressin antagonists
US20070254903A1 (en) 2003-12-23 2007-11-01 Arena Pharmaceuticals, Inc. Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
BRPI0514133A (pt) 2004-08-05 2008-05-27 Hoffmann La Roche compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
US8138342B2 (en) 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP4935356B2 (ja) * 2004-10-13 2012-05-23 ソニー株式会社 再生装置、撮像装置および画面表示方法
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
US8190027B2 (en) 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
CA2615726C (en) * 2005-07-14 2014-05-27 Caterina Bissantz Indol-3-yl-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
US8193208B2 (en) 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
EP2097376A2 (en) * 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
JP2010514727A (ja) * 2006-12-29 2010-05-06 エフ．ホフマン−ラ ロシュ アーゲー アザスピロ誘導体
MX2009007411A (es) * 2007-01-12 2009-07-17 Hoffmann La Roche Derivados de espiropiperidina-glicinamida.

Also Published As

Publication number Publication date
IL198544A (en) 2012-06-28
CA2670674A1 (en) 2008-06-12
CN101547923A (zh) 2009-09-30
NO20091830L (no) 2009-07-06
IL198544A0 (en) 2010-02-17
TW200838518A (en) 2008-10-01
ES2344131T3 (es) 2010-08-18
ZA200903496B (en) 2010-03-31
JP2010511661A (ja) 2010-04-15
EP2102207B1 (en) 2010-06-02
EP2102207A1 (en) 2009-09-23
AU2007328995B2 (en) 2012-04-26
KR20090079255A (ko) 2009-07-21
AU2007328995A1 (en) 2008-06-12
CL2007003482A1 (es) 2008-07-04
US20080139553A1 (en) 2008-06-12
RU2009119394A (ru) 2011-01-20
DE602007006990D1 (de) 2010-07-15
US20080146568A1 (en) 2008-06-19
AR064135A1 (es) 2009-03-18
KR101050568B1 (ko) 2011-07-19
MX2009005504A (es) 2009-06-03
BRPI0720004A2 (pt) 2013-12-17
US20080139554A1 (en) 2008-06-12
US8202993B2 (en) 2012-06-19
ATE469900T1 (de) 2010-06-15
WO2008068185A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
PE20081252A1 (es) Derivados de espiro-piperidina
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
PE20081489A1 (es) Derivados de espiro-piperidina
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR051095A1 (es) Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
AR051092A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
PE20081164A1 (es) Nuevos compuestos 521
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20030847A1 (es) Aza-arilpiperazinas como ligandos del receptor 5ht2
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
ES2179490T3 (es) Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
RU2009125024A (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
AR076860A1 (es) Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
AR047744A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR060318A1 (es) Isoindolonas potenciadoras de receptores metabotropicos de glutamato, composiciones farmaceuticas que las comprenden y el uso de las mismas en la fabricacion de un medicamento para el tratamiento de trastornos neurologicos y psiquiatricos.
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
MX2009009121A (es) Aminoamidas como antagonistas de orexina.

Legal Events

Date Code Title Description
FC Refusal